Philadelphia, PA, July 3, 2012 – Exposure to childhood maltreatment increases the risk for most psychiatric disorders as well as many negative consequences of these conditions. This new study, by Dr. Gustavo Turecki and colleagues at McGill University, Canada, provides important insight into one of the most extreme outcomes, suicide.
"In this study, we expanded our previous work on the epigenetic regulation of the glucocorticoid receptor gene by investigating the impact of severe early-life adversity on DNA methylation," explained Dr. Turecki. The glucocorticoid receptor is important because it is a brain target for the stress hormone cortisol.
The researchers studied brain tissue from people who had committed suicide, some of whom had a history of childhood maltreatment, and compared that tissue to people who had died from other causes. They found that particular variants of the glucocorticoid receptor were less likely to be present in the limbic system, or emotion circuit, of the brain in people who had committed suicide and were maltreated as children compared to the other two groups.
This study also advances the understanding of how the altered pattern of glucocorticoid receptor regulation developed in the maltreated suicide completers. The authors found that the pattern of methylation of the gene coding for the glucocorticoid receptors was altered in the suicide completers with a history of abuse. These DNA methylation differences were associated with distinct gene expression patterns.
Since methylation is one way that genes are switched on or off for long periods of time, it appears that childhood adversity can produce long-lasting changes in the regulation of a key stress response system that may be associated with increased risk for suicide.
"Preventing suicide is a critical challenge for psychiatry. This study provides important new information about brain changes that may increase the risk of suicide," said Dr. John Krystal, Editor of Biological Psychiatry. "It is striking that early life maltreatment can produce these long-lasting changes in the control of specific genes in the brain. It is also troubling that the consequences of this process can be so dire. Thus, it is important that we continue to study these epigenetic processes that seem to underlie aspects of the lasting consequences of childhood adversity."
The article is "Differential Glucocorticoid Receptor Exon 1B, 1C, and 1H Expression and Methylation in Suicide Completers with a History of Childhood Abuse" by Benoit Labonte, Volodymyr Yerko, Jeffrey Gross, Naguib Mechawar, Michael J. Meaney, Moshe Szyf, and Gustavo Turecki (doi: 10.1016/j.biopsych.2012.01.034). The article appears in Biological Psychiatry, Volume 72, Issue 1 (July 1, 2012), published by Elsevier.
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Gustavo Turecki at +1 514 761 6131 ext. 3366 or email@example.com.
The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 4th out of 126 Psychiatry titles and 15th out of 237 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2010 Impact Factor score for Biological Psychiatry is 8.674.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Editorial Office, Biological Psychiatry
+1 214 648 0880
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.